THYMOSIN Alpha-1

Thymosin Alpha-1 (Tα1) is a 28–amino acid thymic peptide investigated for its immunomodulatory properties in preclinical and translational research. Experimental use focuses on T-cell maturation and activation, dendritic-cell priming, and coordination of innate and adaptive responses under infectious, neoplastic, and stressor challenges in controlled laboratory models.

Innate Sensing: Literature evaluates Tα1’s engagement of pattern-recognition pathways (e.g., TLR-linked signaling) in antigen-presenting cells → enhanced antigen processing/presentation and co-stimulatory molecule expression.
Adaptive Modulation: Promotes Th1-biased responses with increases in IL-2/IFN-γ readouts, augmented cytotoxic T-lymphocyte and NK-cell activity, and improved T-cell survival/trafficking metrics in research settings.
Downstream Axes: NF-κB and STAT-associated programs, MHC expression, and interferon-stimulated gene signatures are commonly profiled to quantify immune competence and resilience.
Functional Notes: Experimental designs track changes in dendritic-cell phenotype, TCR signaling thresholds, and effector memory formation.

Antigen presentation and vaccine-adjuvant modeling • Th1/Th2 polarization studies • NK-cell cytotoxicity assays • T-cell development and exhaustion-reversal frameworks • Host-defense and tumor-immune interface models • Cytokine/chemokine network mapping and transcriptional immunoprofiling.

Revitalized Health peptides are produced under cGMP-aligned conditions with pharmaceutical-grade inputs. Each Thymosin Alpha-1 lot is confirmed at ≥99% purity by HPLC with identity verified via LC-MS/MS. Lots undergo appearance/solubility checks and microbial/endotoxin screening to research-grade specifications. Batch-specific Certificates of Analysis provide full method parameters and results for traceability.

Store lyophilized vials at 2–8 °C, protected from light and moisture. After reconstitution with bacteriostatic water, maintain at 2–8 °C and utilize within 20 days. Avoid repeated freeze–thaw cycles to preserve peptide integrity and receptor/target engagement fidelity.

For laboratory research use only. Not intended for human consumption, therapeutic, or diagnostic application. Supplied exclusively to qualified professionals conducting controlled scientific investigations.

Identity: Thymosin α-1 (Tα1; “thymalfasin”), a 28-aa fragment derived from prothymosin-α.
Mode: Engages innate immune pattern-recognition pathways (notably TLR7/9 on plasmacytoid DCs) leading to MyD88-dependent activation of NF-κB and IRF7. Promotes dendritic cell maturation (↑CD80/86, HLA-DR), enhances antigen presentation, shifts toward Th1 responses (↑IL-2/IFN-γ), and augments NK cytotoxicity. Supports T-cell homeostasis and restores function under immunosuppressed states in models.
Analytics: Purity by HPLC; mass confirmation by LC-MS; sequence by Edman/MS; endotoxin by LAL. PD readouts: flow cytometry for DC/T-cell markers (CD80/86, CD3/CD4/CD8), NK activity assays, cytokine panels (IL-2, IFN-γ, TNF-α, IL-12) by ELISA/Luminex; TLR reporter assays. Monitoring: CBC, inflammatory markers, autoimmune symptom review, local tolerability.